Reviewer's report

Title: Comparison of efficacy between different incretin-based therapies; GLP-1 agonists and DPP-4 inhibitors.

Version: 1 Date: 6 June 2012

Reviewer: Sten Madsbad

Reviewer's report:

In the present review GLP-1 receptor agonists and DPP-4 inhibitors are compared in relation to mechanistic differences, and impact of these differences on glycaemic, weight and other cardiometabolic parameters.

The present reviewer has only very few comment on the present review. It is well written and cover the issue very well.

The major point is that so many reviews have been written about the GLP-1 receptor agonist and the DPP-4 inhibitors, also reviews discussion differences between the incretin based therapies. Not quoted in the present review.

One may ask, whether it is necessarily to write a review based on two mechanistic studies, and only two published clinical controlled trials.

Maybe a major part of the first 8 page, which is without any new information, can be shorten.

Regarding Duration 4, if the present reviewer remember correctly it has been published as an abstract (poster presentation) at ADA or EASD.

Page 19, can be rewritten. Many figures for differences in treatment satisfaction is given, but a difference of, i.e. 1.39 (line3) will not make any sense for most readers.

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

During the last 5 years Sten Madsbad has served as a consultant or adviser to: Novartis Pharma, Novo Nordisk, Merck Sharp & Dome, Sanofi-Aventis, AstraZeneca, Johnson & Johnson, Rosche, Mankind, Astra-Zeneca, Boehringer-Ingelheim, Zeeland, E Lilly, Intarcia Therapeutics and have received fee for speaking from Novo Nordisk, Merck, Sharp & Dome, Astra-Zeneca, Johnson and Johnson, Rosche, Shering-Ploug, Sanofi-Aventis, Novartis Pharma, E Lilly, Bristol-Meyer Squibb, AstraZeneca.